减强度移植前使用依马利尤单抗治疗噬血细胞性淋巴组织细胞增多症可改善嵌合状态
该回顾性研究纳入2014至2022年在本机构接受首次减强度预处理造血干细胞移植的50例儿童噬血细胞性淋巴组织细胞增多症患者,其中22例在预处理前21天内接受依马利尤单抗、28例未接受。依马利尤单抗组混合嵌合(48% vs 77%,P=0.03)、严重混合嵌合(5% vs 38%,P<0.01)发生率更低,无干预生存更高(73% vs 43%,P=0.03),总生存差异无统计学意义(82% vs 71%,P=0.39)。
要点
- 移植前使用依马利尤单抗与混合嵌合发生率降低相关(48% vs 77%,P=0.03)。
- 严重混合嵌合发生率在依马利尤单抗组更低(5% vs 38%,P<0.01)。
- 无干预生存依马利尤单抗组更高(73% vs 43%,P=0.03),<12月龄婴儿差异更明显(75% vs 20%,P<0.01)。
核心结论
- 在减强度预处理造血干细胞移植前使用依马利尤单抗治疗噬血细胞性淋巴组织细胞增多症,可降低移植后混合嵌合与移植物失败的风险。
研究设计与样本
- 回顾性研究,纳入2014至2022年在本机构接受首次减强度预处理造血干细胞移植的儿童噬血细胞性淋巴组织细胞增多症患者50例,其中22例在预处理方案前21天内接受依马利尤单抗,28例未接受。
主要发现
- 混合嵌合(供者嵌合<95%)发生率依马利尤单抗组为48%,未使用组为77%(P=0.03)。
- 严重混合嵌合(供者嵌合<25%)发生率依马利尤单抗组为5%,未使用组为38%(P<0.01)。
- 无干预生存(包含供者淋巴细胞输注、供者CD34选择细胞输注、第二次造血干细胞移植或移植后5年内死亡)依马利尤单抗组为73%,未使用组为43%(P=0.03)。
- 在<12月龄婴儿中,无干预生存依马利尤单抗组为75%,未使用组为20%(P<0.01)。
- 总生存依马利尤单抗组为82%,未使用组为71%,差异无统计学意义(P=0.39)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory disorder driven by interferon gamma (IFN-γ). Emapalumab, an anti-IFN-γ antibody, is approved for the treatment of patients with primary HLH. Hematopoietic stem cell transplantation (HSCT) is required for curing HLH. Reduced-intensity conditioning (RIC) HSCT is associated with improved survival but higher incidences of mixed chimerism and secondary graft failure. To understand the potential impact of emapalumab on post-HSCT outcomes, we conducted a retrospective study of pediatric patients with HLH receiving a first RIC-HSCT at our institution between 2014 and 2022 after treatment for HLH, with or without this agent. Mixed chimerism was defined as <95% donor chimerism and severe mixed chimerism as <25% donor chimerism. Intervention-free survival (IFS) included donor lymphocyte infusion, infusion of donor CD34-selected cells, second HSCT, or death within 5 years after HSCT. Fifty patients met the inclusion criteria; 22 received emapalumab within 21 days before the conditioning regimen, and 28 did not. The use of emapalumab was associated with a markedly lower incidence of mixed chimerism (48% vs 77%; P = .03) and severe mixed chimerism (5% vs 38%; P < .01). IFS was significantly higher in patients receiving emapalumab (73% vs 43%; P = .03). Improved IFS was even more striking in infants aged <12 months, a group at the highest risk for mixed chimerism (75% vs 20%; P < .01). Although overall survival was higher with emapalumab, this difference was not significant (82% vs 71%; P = .39). We show that the use of emapalumab for HLH before HSCT mitigates the risk of mixed chimerism and graft failure after RIC-HSCT.
引用
- Verkamp B, Jodele S, Sabulski A, et al. Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism. Blood. 2024. PMID: 39190435. doi:10.1182/blood.2024025977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。